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Background: Cutaneous T-cell lymphomas (CTCL), with few exceptions, remain incurable and treatment 
is largely palliative. We performed a retrospective analysis of systemic treatment outcomes of patients 
diagnosed with MF/SS at the University of Michigan. 
Methods: We identified 223 patients with MF/SS evaluated at the University of Michigan from 1997-
2013. Disease stage at diagnosis, time of treatment, treatments received and reasons for treatment 
cessation were retrospectively analyzed using our CTCL database. The primary endpoint was time to 
next treatment (TTNT). Treatment outcomes were analyzed using Kaplan-Meier method and 
comparisons among groups were made using log-rank analysis. 
Results: A superior time to next treatment (TTNT) was associated with retinoid (47.2 months) or 
interferon (21.7 months) therapies when compared with HDAC inhibitors (6.4 months) or systemic 
chemotherapy (5.1 months). Retinoids and interferon were associated with superior TTNT in both 
limited-stage (62.7 and 32.6 months, respectively) and advanced stage (22.1 months and 14.9 months, 
respectively) disease. ECP had a superior TTNT in Sezary Syndrome (17.5 months). HDAC inhibitors and 
chemotherapy were associated with inferior TTNT in both limited stage disease (3.3 months and 4.1 
months, respectively) and advanced stage disease (8.2 months and 5.4 months, respectively).  
Conclusions: With the exception of interferon, retinoids, or ECP, durable responses are rarely achieved 
with systemic therapies in MF/SS patients, particularly those with advanced-stage disease. Therefore, 
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 Primary cutaneous T cell lymphomas (CTCL) are a heterogenous group of extranodal T-cell 
lymphomas involving the skin
1
. Cutaneous manifestations are variable, including patches/plaques, 
tumors, or diffuse erythroderma. Nodal, peripheral blood, or internal organ involvement is less common. 
The incidence rate of CTCL is around 10 per one million persons, with Mycosis Fungoides (MF) and 
Sezary Syndrome (SS) comprising over half of all CTCL diagnoses
2
.  
 Risk-stratification in MF/SS is largely based on TNMB staging, although other variables including 
gender, age, and folliculotropic disease also are prognostic and are included in the cutaneous lymphoma 
international prognostic index (CLIPi)
3
. Patients with patches/plaques involving <10% of body surface 
area (stage IA) may anticipate an overall survival comparable to age matched controls. In contrast, 
overall survival in the setting of advanced-stage disease with visceral organ involvement is dismal, as 
responses to most currently available therapies are incomplete and rarely durable
4
. The risk of disease 
progression  increases with increasing tumor (T) stage, with only 10% of patients with T1 disease 
undergoing progression to a higher T stage in comparison to approximately 80% in the setting of tumor 
stage (T3)disease
5
. Thus, the vast majority of patients with limited-stage disease (IA-IIA) may be 
conservatively managed with local skin-directed therapies. Progression to advanced-stage disease may 
be anticipated in approximately 24% of these patients
4
. Patients with advanced-stage disease (IIB-IV) 
may benefit from systemic treatments for disease control and symptom palliation. Unfortunately,  
treatment failure and eventual disease progression is common, highlighting the need for improved 
therapeutic strategies.  
  Skin-directed therapies (SDT), including topical steroids, PUVA, UVB, radiation and topical 
chemotherapies are used for localized disease control while systemic therapies are reserved for both 
limited-stage disease that is poorly controlled with skin-directed therapies alone and advanced-stage 









, and antibody-based therapies
14; 
15
. For Sezary syndrome, extracorporeal photophoresis (ECP) is frequently used in the front-line setting
16
. 
In contrast to most alternative therapies, which are largely palliative, allogeneic stem cell 
transplantation is potentially curative
17; 18
. Unfortunately, as MF/SS are rare lymphomas, few 
randomized clinical trials have been conducted and most of these trials involved patients with early 
stage disease
19
. Treatment guidelines are available but the evidence supporting these are largely based 
on data obtained from phase 2 clinical trials or retrospective studies
20-22
.  
 Conventional chemotherapeutic agents, given alone or in combination, are generally not 
appropriate first-line options in  MF/SS
23
. In MF, early aggressive therapy with radiation and multi agent 
chemotherapy does not improve disease-free or overall survival and is associated with considerable 
toxicity
24
. As the therapeutic armamentarium continues to expand, we sought to retrospectively 
compare outcomes among MF/SS patients treated with various systemic therapies. 
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 We retrospectively reviewed records of our CTCL database to identify pathologically confirmed 
mycosis fungoides (MF) and Sezary Syndrome cases (SS). In all, 223 cases of pathologically confirmed 
CTCL and MF were identified, diagnosed over the years spanning 1997-2013. Patient data were obtained 
including age, gender, TNMB stage, skin directed treatments (SDT) and systemic treatments with date of 
initiation, time of treatment discontinuation and reason for discontinuation, and date of last follow up 
or date of death. 
Systemic treatment analysis 
 Systemic treatments were classified as chemotherapy, biological response modifiers (oral 
retinoids, interferon), HDAC inhibitors, denileukin diftitox, and extracorporeal photopheresis (ECP). The 
line of treatment was determined by counting the number of systemic treatments the patient 
underwent prior to the treatment being considered. SDTs were not included when determining the line 
of therapy. In several instances, two therapies were initiated simultaneously: retinoid and denileukin 
diftitox, n=5; retinoid plus interferon, n=3; ECP plus HDAC inhibitor, n=3; retinoid plus methotrexate, 
n=2; retinoid plus ECP, n=1. These cases were still included in their respective individual systemic 
treatment group. Treatments used in less than 10 patients (oral methotrexate, n=7; brentuximab, n=6) 
were not analyzed further. 
Data analysis 
 Time to next treatment (TTNT) was defined as the time from the date of treatment initiation to 
the time of initiation of the next systemic treatment or time of death, whichever occurred first.  
Initiation of a new SDT during a systemic treatment for local control was not regarded as a treatment 
failure, as long as the systemic treatment was continued during this time and a new systemic treatment 
was not initiated. However, the need for Total Skin Electron Beam therapy (TSEB) was considered as a 
systemic treatment failure. If treatment was discontinued due to disease progression and no further 
therapy pursued, the date when systemic treatment was discontinued was used in the TTNT analysis. 
Patients were otherwise censored at the time of last follow up.  
 Statistical analysis was carried out using JMP Pro, version 10. Survival analyses were performed 
using the Kaplan-Meier method with pair wise comparisons between treatment groups using the log-
rank test, with p value of <0.05 considered to statistically significant. We excluded treatment groups 
with fewer than 5 patients in survival analyses. 
 
 
Page 4 of 14
John Wiley & Sons
American Journal of Hematology













 Table I shows the characteristics of the patients included in this study. Median follow up time 
for the study was 4.2 years. Most patients identified had limited stage (stage I-IIA) disease at the time of 
diagnosis and treatment (79.8%). The vast majority of the patients were diagnosed with Mycosis 
fungoides (MF) (94.2%). Of the 223 patients, 135 were managed with skin directed therapies (topical 
steroids, localized XRT) alone. Of the 88 patients that received some form of systemic therapy, patients 
with limited stage disease on average underwent 2 lines of treatment (range 1-8) while patients with 
extensive stage disease on average underwent 3 lines of treatment (range: 1-7). As anticipated, patients 
with limited stage disease experienced a superior 3 year overall survival (94.8%) as compared to those 
with advanced-stage disease (54.8%). 
Treatment Analysis 
 Of the 88 patients treated with systemic treatments, we identified 214 different episodes of 
treatment with various agents: oral retinoids, interferon, chemotherapy, HDAC inhibitors, denileukin 
diftitox, and ECP (Table II). Regarding the specific groups of systemic treatments, the oral retinoid 
treatment group included patients treated with acitretin, n=30; bexarotene, n=36; and isotretinoin, n=2. 
The HDAC inhibitor group included patients treated with vorinostat (n=22) and romidepsin (n=6). The 
chemotherapy group included patients treated with either single agent [pralatrexate (n=9), gemcitabine 
(n=14), liposomal doxorubicin (n=6), fludarabine (n=1)] or multi agent [(PEP-C
25
 (n=12), CHOP (n=5), CVP 
(n=1), CHOEP (n=1), EPOCH (n=1), and ICE (n=1)] chemotherapy.  
 Oral retinoids were the most common therapy, most often used in the setting of limited disease 
as a first line therapy. Not surprisingly, most treatments were used in the setting of advanced stage 
disease. ECP was the most common first line treatment in Sezary Syndrome. The other treatments were 
most often used as second and higher line treatments.  
All treatments.  
 Overall, retinoids were associated with the longest mean time to next treatment (TTNT) at 47.2 
months and highest number of patients free from next treatment (FFTNT) at one year (75.0%) which 
was superior to all treatments (Figure 1, Supplementary table 1). Interferon had a relatively long TTNT at 
21.7 months and was superior to chemotherapy and HDAC inhibitors. Chemotherapy had the shortest 
mean TTNT at 5.1 months and was had a statistically significantly lower TTNT when compared to ECP, 
interferon, and retinoids. HDAC inhibitors also had a short mean TTNT at 6.4 months with the lowest 
FFNT at one year (3.6%) and was statistically inferior to all treatments except for chemotherapy and 
denileukin diftitox. Denileukin diftitox had an intermediate TTNT (9.6 months), with 17.6% of patients 
who were FFNT at one year, suggesting  heterogeneity in  response among patients.  
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Limited Stage disease.  
 When comparing treatments in the setting of limited-stage disease, retinoids had the longest 
mean TTNT at 62.7 months with FFNT at one year of 90.5% and was statistically superior to all 
treatments, including interferon, HDAC inhibitors and chemotherapy (Figure 2, Supplementary table 2). 
Interferon had a statistically significant superior TTNT compared to chemotherapy and HDACi at 32.6 
months with a FFNT at one year of 50%. Both HDAC inhibitors and chemotherapy had relatively short 
TTNT in limited stage disease (3.3 months and 4.1 months, respectively). All limited stage disease 
patients failed therapy with HDAC inhibitors by one year, while only 6.2% of patients treated with 
chemotherapy were FFNT at one year.  
Extensive Stage disease.  
 Among patients with advanced-stage disease, retinoids had the longest mean TTNT at 22.1, and 
was statistically significantly longer compared to chemotherapy and HDACi (Figure 3, Supplementary 
Table 3). Both ECP and interferon had intermediate mean TTNT at 17.5 and 14.9 and both were 
statistically significant compared to chemotherapy, while ECP was also statistically significant compared 
to HDACi.  Denileukin diftitox had an intermediate mean TTNT at 10.0, but was not statistically 
significant compared to any of the other treatments. With denileukin diftitox, there were 3 of 14 
patients who were FFNT at the end of one year, indicating a subset of patients who may have long term 
benefit with this therapy. As with limited stage disease, both chemotherapy and HDACi had relatively 
short mean TTNT, at 5.4 months and 8.2 months, respectively.  
Transplant Experience  
 We identified four patients who underwent allogeneic bone marrow transplant at our institution, 
three for extensive stage MF and one for SS. Two underwent matched related donors (ages 34 and 40) 
and two unrelated donor transplants (ages 60 and 62 years). All patients were heavily pretreated (>4 
systemic treatments) prior to undergoing transplant. Two patients experienced disease progression 
within one year of transplant. Two patients are alive and disease free and have not required further 
systemic therapy post-transplant.  









 line of therapy) for interferon, HDAC inhibitors, and chemotherapy (data not shown). Retinoids were 
not included in the analysis as it was used very rarely as a late line treatment. We did not observe a 
statistically significant difference in the TTNT between early line and late line therapy.We also reviewed 
the reason for treatment discontinuation among the different treatments (data not shown). 
Unexpectedly, HDAC inhibitors had a higher toxicity rate leading to treatment discontinuation (30.8%) 
compared to chemotherapy (17.3%), with GI side effects being the most common toxicity. For 
denileukin diftitox treatment, vascular leak syndrome accounted for all the treatment toxicity related 
discontinuation in this group. 
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 In this study, we retrospectively analyzed outcomes in systemically treated  MF/SS patients from  
a single institution, including those treated with conventional chemotherapeutic agents, biologic 
response modifiers (e.g. retinoids and interferon), and HDAC inhibitors. There have been very few 
randomized clinical trials directly comparing commonly used therapies in MF/SS, making rational 
treatment decisions difficult. The increasing number of novel therapies currently available, or on the 
horizon, further compounds this challenge
14; 26
. We used TTNT as primary endpoint as this is a clinically 
meaningful surrogate which incorporates both disease progression and symptom control into a single 
endpoint. In addition, TTNT can be determined more accurately in a retrospective study than other 
objective endpoints, such as the modified Severity Weights Assessment Tool (mSWAT)
27
. Disadvantages 
of TTNT include variability from clinician to clinician based on treatment practices and data skewing at a 
single institution due to a limited number of providers treating a rare disease. However, cases and 
treatment decisions were frequently discussed at a multi-disciplinary CTCL tumor board, thus reducing 
single provider treatment bias. 
 We demonstrate that both chemotherapy and HDACi are associated with poor outcomes. For 
chemotherapy, the median TTNT is 5.1 months with 92.5% of patients requiring alternative therapy at 1 
year. Long term responses were very few despite the respectable response rates reported with these 
agents in prior studies
11; 28-30
.  These results reiterate the very poor efficacy of chemotherapy in MF and 
SS, with no specific chemotherapeutic regimen providing a durable response, likely due to inherent 
mechanisms of resistance that are poorly understood. For HDAC inhibitors, the median TTNT is 6.4 
months with 96.4% of patients requiring alternate therapy at 1 year. One of the reasons for this poor 
outcome may have been the high rate of discontinuation due to toxicity (30.8%), mostly secondary to GI 
side effects. Very few durable responses were achieved with HDAC inhibitors. Collectively, the findings 
reported here are consistent with those reported by Hughes et. al.
20
. In this large retrospective study, a 
similarly poor TTNT was observed with chemotherapy (3.9 months) and HDAC inhibitors (4.5 months) .  
 In contrast, biologic response modifiers were well tolerated and associated with superior TTNT.  
In selected patients, retinoids, interferon, and ECP provided durable responses. Importantly, when 
retinoids and interferon were further analyzed in the setting of limited and extensive stage disease, their 
superior TTNTs persisted. Consistent with Hughes et al.
20
,  we did not find a difference in treatment 
effect between early line and late line interferon treated patients, suggesting interferon can be used 
with similar efficacy in treatment naïve patients and as a salvage option in more heavily pre-treated 
patients. These data support current guidelines recommending the use of retinoids and interferon in 
MF/SS.  
 This study has several limitations. Our sample sizes were generally quite small limiting the 
power of our study, particularly after stratifying  patient groups based on disease stage. Although 
retinoids had a superior TTNT, they were predominantly used in patients with limited-stage disease, and 
at lower doses (data not shown) in patients undergoing skin-directed therapy with UV irradiation. 
Therefore, it is not surprising that retinoids were associated with a prolonged TTNT in this patient 
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population. Treatment heterogeneity, particularly among conventional chemotherapeutic agents, and 
the small sample size preclude comparisons of specific agents.  
 The therapeutic arsenal for MF and SS continues to expand. A number of novel agents are 
currently in development for both limited and extensive stage disease
14; 26
.  A number of 
immunotherapies are currently in clinical trials, including checkpoint  blockade, brentuximab vedotin 
(anti-CD30), mogamulizumab (anti-CCR4),  resimmune (anti-CD3)
15; 31; 32
, and  novel targeted agents
26; 33
. 
Cytogenetic and genomic studies have revealed interesting insights into potential molecular targets
1; 34; 
35
. However, extensive disease heterogeneity of MF/SS may indicate that future treatment approaches 
may need to be personalized, targeting specific molecular alterations or the tumor microenvironment. 
Clinical trial participation should be encouraged, as the TTNT is brief and few durable responses are 
achieved for most currently available agents.   
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Figure 1. TTNT analysis for all stages. (A) Mean TTNT +/- CI for each treatment. (B) Kaplan Meier curves for 
each treatment with p values from log rank comparisons shown in C. Both retinoids and interferon had a 
superior TTNT compared to the other therapies.  
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Figure 2. TTNT analysis for limited stage disease. (A) Mean TTNT +/- CI for each treatment. (B) Kaplan 
Meier curves for each treatment with p values from log rank comparisons shown in C. Both retinoids and 
interferon had a superior TTNT compared to chemotherapy and HDAC inhibitors.  
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Figure 3. TTNT analysis for advanced stage disease. (A) Mean TTNT +/- CI for each treatment. (B) Kaplan 
Meier curves for each treatment with p values from log rank comparisons shown in C. Retinoids and ECP had 
a superior TTNT compared to chemotherapy and HDAC inhibitors.  
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